JPWO2020074697A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020074697A5
JPWO2020074697A5 JP2021517030A JP2021517030A JPWO2020074697A5 JP WO2020074697 A5 JPWO2020074697 A5 JP WO2020074697A5 JP 2021517030 A JP2021517030 A JP 2021517030A JP 2021517030 A JP2021517030 A JP 2021517030A JP WO2020074697 A5 JPWO2020074697 A5 JP WO2020074697A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
score
patient
use according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021517030A
Other languages
English (en)
Japanese (ja)
Other versions
JP7500550B2 (ja
JP2022502421A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/077578 external-priority patent/WO2020074697A1/en
Publication of JP2022502421A publication Critical patent/JP2022502421A/ja
Publication of JPWO2020074697A5 publication Critical patent/JPWO2020074697A5/ja
Priority to JP2024091857A priority Critical patent/JP2024116245A/ja
Application granted granted Critical
Publication of JP7500550B2 publication Critical patent/JP7500550B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517030A 2018-10-12 2019-10-11 乾性眼疾患の治療のための眼科用組成物 Active JP7500550B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024091857A JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18200154 2018-10-12
EP18200154.5 2018-10-12
EP18202263.2 2018-10-24
EP18202263 2018-10-24
EP19167551.1 2019-04-05
EP19167551 2019-04-05
PCT/EP2019/077578 WO2020074697A1 (en) 2018-10-12 2019-10-11 Ophthalmic composition for treatment of dry eye disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024091857A Division JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Publications (3)

Publication Number Publication Date
JP2022502421A JP2022502421A (ja) 2022-01-11
JPWO2020074697A5 true JPWO2020074697A5 (ru) 2023-08-16
JP7500550B2 JP7500550B2 (ja) 2024-06-17

Family

ID=68138117

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517030A Active JP7500550B2 (ja) 2018-10-12 2019-10-11 乾性眼疾患の治療のための眼科用組成物
JP2024091857A Pending JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024091857A Pending JP2024116245A (ja) 2018-10-12 2024-06-05 乾性眼疾患の治療のための眼科用組成物

Country Status (11)

Country Link
US (2) US11413323B2 (ru)
EP (2) EP3863658B1 (ru)
JP (2) JP7500550B2 (ru)
CN (1) CN112823020A (ru)
AU (1) AU2019358249B2 (ru)
CA (1) CA3112031A1 (ru)
ES (1) ES2974839T3 (ru)
IL (1) IL281773A (ru)
PH (1) PH12021550620A1 (ru)
SG (1) SG11202102820VA (ru)
WO (1) WO2020074697A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
EP3687496A1 (en) 2017-09-27 2020-08-05 Novaliq GmbH Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
KR20230142548A (ko) 2021-02-03 2023-10-11 에이디에스 테라퓨틱스 엘엘씨 국소 안과용 조성물
WO2024170514A1 (en) * 2023-02-13 2024-08-22 Novaliq Gmbh Ophthalmic composition for ocular surgery preparation in patients with ocular surface disease

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2616927A (en) 1950-05-12 1952-11-04 Minnesota Mining & Mfg Fluorocarbon tertiary amines
US4452818A (en) 1982-03-19 1984-06-05 Haidt Sterling J Extraocular method of treating the eye with liquid perfluorocarbons
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US5077036A (en) 1986-01-14 1991-12-31 Alliance Pharmaceutical Corp. Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid
JPH0764702B2 (ja) 1986-04-23 1995-07-12 鐘紡株式会社 多相乳化型化粧料
JPS6452722A (en) 1987-05-01 1989-02-28 Anjierini Pharmaceut Inc Ophthalmic composition
JPH03279323A (ja) 1989-12-15 1991-12-10 Johnson & Johnson Consumer Prod Inc 日焼け止め組成物
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5518731A (en) 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
US6458376B1 (en) 1990-09-27 2002-10-01 Allergan, Inc. Nonaqueous fluorinated drug delivery suspensions
US5152997A (en) 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
GB9114374D0 (en) 1991-07-03 1991-08-21 Smithkline Beecham Plc Novel process
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
FR2679150A1 (fr) 1991-07-17 1993-01-22 Atta Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations.
US6602900B2 (en) 1992-09-21 2003-08-05 Allergan, Inc. Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5336175A (en) 1992-10-29 1994-08-09 Mames Robert N Method for the treatment of retinal detachments
US5370313A (en) 1994-01-10 1994-12-06 Beard; Walter C. Sterile liquid dispenser
DE4405627A1 (de) 1994-02-22 1995-08-24 Hoechst Ag Fluorkohlenwasserstoffe enthaltende Ölemulsionen
FR2720943B1 (fr) 1994-06-09 1996-08-23 Applic Transferts Technolo Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples.
US5849291A (en) 1994-10-17 1998-12-15 Symbollon Corporation Opthalmic non-irritating iodine medicament
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
FR2752161B1 (fr) 1996-08-07 1998-09-25 Atta Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles
US5863560A (en) 1996-09-11 1999-01-26 Virotex Corporation Compositions and methods for topical application of therapeutic agents
IN184589B (ru) 1996-10-16 2000-09-09 Alza Corp
AU750039B2 (en) 1997-02-04 2002-07-11 Murray A. Johnstone Method of enhancing hair growth
DE19709704C2 (de) 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
US6645963B2 (en) 1997-11-05 2003-11-11 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
US5851544A (en) 1997-12-18 1998-12-22 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic skin or hair care compositions containing fluorocarbons infused with carbon dioxide
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
BR9904780A (pt) 1998-02-09 2000-03-08 Macrochem Corp Esmalte fungicida para unhas e método de uso do mesmo
DE19861012A1 (de) 1998-03-18 1999-09-30 Pharm Pur Gmbh Behandlungsmittel für die Ophthalmologie
CN1221249C (zh) 1998-08-19 2005-10-05 斯凯伊药品加拿大公司 普鲁泊福的可注射水分散体
US6140374A (en) 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
ATE322889T1 (de) 1999-02-08 2006-04-15 Alza Corp Stabile nicht wässerige einphasige visköse vehikeln und formulierungen die diese vehikeln verwenden
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
AU3898700A (en) 1999-03-15 2000-10-04 John Claude Krusz Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages
US6177477B1 (en) 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
DE19926890C1 (de) 1999-06-12 2000-07-27 Pharm Pur Gmbh Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6528086B2 (en) 1999-09-28 2003-03-04 Zars, Inc. Methods and apparatus for drug delivery involving phase changing formulations
JP2001158734A (ja) 1999-12-02 2001-06-12 Lion Corp 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
AU2603301A (en) 1999-12-22 2001-07-03 Alcon Universal Limited 6-keto prostaglandin F1alpha and analogs for treating dry eye
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE10024413A1 (de) 2000-05-19 2001-12-06 Mika Pharma Gmbh Pharmazeutische und/oder kosmetische Zubereitung
DE10042412B4 (de) 2000-08-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Abgabe von Venlafaxin, und seine Verwendung
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20030027833A1 (en) 2001-05-07 2003-02-06 Cleary Gary W. Compositions and delivery systems for administration of a local anesthetic agent
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
CN1703206A (zh) 2001-09-04 2005-11-30 泰姆斯多夫药品有限公司 治疗指甲生长功能紊乱失调的膏药
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP3998596B2 (ja) 2003-03-31 2007-10-31 日本ペイント株式会社 塗膜ムラの算出式算出方法及び塗膜ムラの数値化方法
EP1663148A2 (en) 2003-08-25 2006-06-07 Foamix Ltd. Penetrating pharmaceutical foam
US20050079210A1 (en) 2003-10-09 2005-04-14 Gupta Shyam K. Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients
NZ546106A (en) 2003-10-10 2008-10-31 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
AU2004293027A1 (en) 2003-11-19 2005-06-09 Barnes-Jewish Hospital Enhanced drug delivery
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
WO2005099718A1 (en) 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (ja) 2004-06-08 2008-01-24 オキュラリス ファーマ, インコーポレイテッド 疎水性眼用組成物および使用方法
US7063241B2 (en) 2004-06-10 2006-06-20 Allergan, Inc. Dispensing tip
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
US7740875B2 (en) 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
EP1688161A1 (en) 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
GB0511499D0 (en) 2005-06-06 2005-07-13 Medpharm Ltd Topical ungual formulations
ES2318802T3 (es) 2005-08-05 2009-05-01 BHARAT SERUMS & VACCINES LTD. Composiciones de emulsion de propofol intravenosas que tienen eficacia conservante.
FR2892023B1 (fr) 2005-10-14 2009-09-25 Galderma Sa Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale
DE102005050431A1 (de) 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
DE102005055811A1 (de) 2005-11-23 2007-05-31 Novaliq Gmbh Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen
TWI376239B (en) 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
KR20090053892A (ko) 2006-07-25 2009-05-28 오스모티카 코프. 점안액
EP2046290A4 (en) 2006-08-04 2011-08-17 Insys Therapeutics Inc AQUEOUS DRONABINOL FORMULATIONS
CA2664879C (en) 2006-09-29 2015-03-24 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
US9000048B2 (en) 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
AU2007330356B2 (en) 2006-12-07 2013-05-02 Sun Pharma Advanced Research Company Ltd Metered drop bottle for dispensing microliter amounts of a liquid in the form of a drop
CN200977281Y (zh) 2006-12-08 2007-11-21 陈宇 带助滴器的滴眼瓶
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
US8222292B2 (en) 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
DE102007055046A1 (de) 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
US20090136430A1 (en) 2007-11-27 2009-05-28 Dugger Harry A Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US9309313B2 (en) 2008-01-09 2016-04-12 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
ATE532505T1 (de) 2008-04-18 2011-11-15 Novaliq Gmbh Inhalative und instillative verwendung von semifluorierten alkanen als wirkstoffträger im intrapulmonalen bereich
US20100006600A1 (en) 2008-07-14 2010-01-14 Dascanio Gustavo A Fluid dispenser including hydrophobic ring
JP5739344B2 (ja) 2008-10-31 2015-06-24 ザ ユニヴァーシティー オブ ミシシッピ Δ−9−thc−アミノ酸エステルを含む組成物及び調製方法
CA2743824A1 (en) 2008-11-26 2010-06-03 Surmodics, Inc. Implantable ocular drug delivery device and methods
JP5670200B2 (ja) 2008-12-02 2015-02-18 ロート製薬株式会社 眼科用組成物
US8501800B2 (en) 2009-03-05 2013-08-06 Insite Vision Incorporated Controlled-release ophthalmic vehicles
IT1393419B1 (it) 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
PL2429317T5 (pl) 2009-04-17 2019-09-30 Natac Pharma, S.L. Kompozycje bogate w kwasy tłuszczowe omega 3 z niską zawartością kwasu fitanowego
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP5736635B2 (ja) 2009-06-25 2015-06-17 ライオン株式会社 ドライアイ治療剤
KR101702157B1 (ko) 2009-06-25 2017-02-13 라이온 가부시키가이샤 안과용 조성물
US20110269704A1 (en) 2009-07-24 2011-11-03 Seigfried Bernd G Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically
JP2011024841A (ja) 2009-07-28 2011-02-10 健太 ▲浜崎▼ 点眼補助具
EP2332525A1 (en) 2009-11-23 2011-06-15 Novaliq GmbH Pharmaceutical composition comprising propofol
EP2335735A1 (en) * 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
CN102869345B (zh) 2010-03-17 2015-02-11 诺瓦利克有限责任公司 用于治疗眼内压增高的药物组合物
DE102010022567A1 (de) 2010-06-02 2011-12-08 Fluoron Gmbh Zubereitung
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
TR201808752T4 (tr) 2011-01-04 2018-07-23 Novaliq Gmbh Semiflorlanmış alkanları içeren o/w emülsiyonları.
CA2834855C (en) 2011-05-25 2020-12-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
CA2834862C (en) 2011-05-25 2019-12-17 Novaliq Gmbh Pharmaceutical composition for administration to nails
CN202136470U (zh) 2011-06-08 2012-02-08 天津市金亿达药用包装材料有限公司 便于滴药的眼药瓶
US8758826B2 (en) 2011-07-05 2014-06-24 Wet Inc. Cannabinoid receptor binding agents, compositions, and methods
JP6084987B2 (ja) 2012-01-23 2017-02-22 ノバリック ゲーエムベーハー セミフッ素化アルカンに基づく安定化タンパク質組成物
US9549966B2 (en) 2012-02-21 2017-01-24 Massachusetts Eye & Ear Infirmary Inflammatory eye disorders
US9878000B2 (en) 2012-06-20 2018-01-30 University Of Waterloo Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof
CA2883002C (en) 2012-09-12 2019-05-21 Novaliq Gmbh Compositions comprising mixtures of semifluorinated alkanes
ES2745084T3 (es) 2012-09-12 2020-02-27 Novaliq Gmbh Composiciones de alcanos semifluorados para uso en el tratamiento de la queraconjuntivitis seca
AU2013362909A1 (en) 2012-12-18 2015-05-21 Novartis Ag Compositions and methods that utilize a peptide tag that binds to hyaluronan
DK2968650T3 (en) 2013-03-14 2019-03-11 Panoptica Inc EYE PHARMACEUTICAL FORMULATIONS FOR THE POSTERIOR EYE SEGMENT
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
KR102272568B1 (ko) 2013-07-23 2021-07-05 노바리크 게엠베하 안정화 항체 조성물
CN106061490A (zh) 2013-10-09 2016-10-26 列奥尼达斯·A·约翰逊 一种治疗和预防眼部疾病症状或体征的方法及组合物
CN203524843U (zh) 2013-10-20 2014-04-09 吕相瑜 自助滴眼液辅助支架
WO2015074137A1 (en) 2013-11-20 2015-05-28 Mary Lynch Compositions and methods for treatment of ocular inflammation and pain
CA2943255C (en) 2014-03-31 2023-01-24 Amcor Limited Controlled release container
EP2944324A1 (de) 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen
US10123904B2 (en) 2014-08-13 2018-11-13 University Of Florida Research Foundation, Inc. Preservative removal from eye drops
EP3209331B1 (en) 2014-10-20 2023-07-12 Sentiss Pharma Private Limited Ophthalmic solution
MA41299A (fr) 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
DK3356313T3 (da) 2015-09-30 2020-07-20 Novaliq Gmbh 2-perfluorhexyloktan til oftalmisk indgivelse
WO2017066429A1 (en) 2015-10-14 2017-04-20 Paul Gavaris Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
WO2017135918A1 (en) 2016-02-04 2017-08-10 Dyer Gordon Wayne Method for impairing a cassie-baxter state
KR102257916B1 (ko) 2016-06-23 2021-05-28 노바리크 게엠베하 드롭 디스펜서를 포함하는 키트
AU2017329772B2 (en) 2016-09-22 2023-02-02 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
JP2019534867A (ja) 2016-09-28 2019-12-05 ノバリック ゲーエムベーハー カンナビノイド受容体結合リガンドを含む組成物
MX2019007586A (es) 2016-12-22 2019-12-11 Novaliq Gmbh Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2019007587A (es) * 2016-12-23 2019-12-16 Novaliq Gmbh Composicion oftalmica para el tratamiento de la enfermedad del ojo seco.
EP3612228B1 (en) 2017-04-21 2023-08-23 Dermaliq Therapeutics, Inc. Iodine compositions
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
WO2019166631A1 (en) 2018-03-02 2019-09-06 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease

Similar Documents

Publication Publication Date Title
US8524758B2 (en) Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia
EA023607B1 (ru) Применение фотоусиливающих агентов при перекрестном сшивании роговицы
CN112823020A (zh) 用于治疗干眼病的眼用组合物
AU2006260184B2 (en) Prophylactic or therapeutic agent for corneal/conjunctival disease
CA2806942A1 (en) Compounds for the treatment/prevention of ocular inflammatory diseases
JPWO2020074697A5 (ru)
US20220175734A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
US20220257593A1 (en) Carabachol-bromonidine formulation to enhance anti-presbyopia effects
Butrus et al. Vernal keratoconjunctivitis and keratoconus
EP2598117A2 (en) Preservative free bimatoprost solutions
Bruce et al. Anterior eye disease and therapeutics AZ
Gillies et al. Topical interferon alpha 2b for corneal haze after excimer laser photorefractive keratectomy
JPWO2020058504A5 (ru)
WO2016009982A1 (ja) 角結膜障害治療剤
RU2817992C1 (ru) Способ лечения синдрома сухого глаза, обусловленного длительным ношением мягких контактных линз
RU2607291C1 (ru) Способ лечения первичной глаукомы у больных с сопутствующей артериальной гипертензией
US20230210821A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
JP2019038783A (ja) ドライアイの治療剤
Kabat Lacrimal occlusion therapy for the treatment of superior limbic keratoconjunctivitis
Laughrea et al. Iatrogenic ocular silver nitrate burn
RU2021107211A (ru) Офтальмологические композиции для лечения синдрома сухого глаза
TW202228659A (zh) 乾眼症之預防劑、改善劑及治療劑
Mannis et al. Superficial hypertrophic dendriform epitheliopathy post-keratoplasty
RU2021107208A (ru) Офтальмологические композиции для лечения повреждения поверхности глаза и симптомов сухости глаз
KR20080074128A (ko) 각결막 장애 치료제